Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL).   This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients...

Read More

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Read More

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Posted by on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs).  This study concluded that ponatinib was effective in heavily pretreated patients when administered in any phase of...

Read More

Evaluating the long-term effectiveness of ibrutinib–rituximab treatment versus standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Evaluating the long-term effectiveness of ibrutinib–rituximab treatment versus standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Posted by on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the long-term effectiveness of ibrutinib (Imbruvica)–rituximab (Rituxan) (IR) treatment versus standard chemoimmunotherapy (CIT) in patients aged 70 or younger with previously untreated chronic lymphocytic leukemia (CLL). The data showed that the IT regimen significantly improved the survival outcomes compared...

Read More

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Posted by on Sep 17, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of salvage treatment using either chemotherapy (CT) or allogeneic hematopoietic stem cell transplant (allo-HSCT) on the overall outcome in patients with refractory (unresponsive) acute myeloid leukemia (AML).  This study concluded that allo-HSCT benefits these patients and that direct...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Infusion reactions and effectiveness of front-line obinutuzumab and chlorambucil for chronic lymphocytic leukemia

Infusion reactions and effectiveness of front-line obinutuzumab and chlorambucil for chronic lymphocytic leukemia

Posted by on May 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate infusion reactions and the effectiveness of the combination of obinutuzumab (Gazyva) and chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL).  This study concluded that first dose infusion reactions with obinutuzumab can be reduced by using chlorambucil first and by using a very...

Read More

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Posted by on Apr 26, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive).  This study concluded that the...

Read More

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Posted by on Apr 10, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate optimized conformal (OC) total body irradiation (TBI) in pediatric patients with blood cancers who received further chemotherapy and allogeneic hematopoietic stem cell transplant (alloHSCT) with TCRαβ/CD19 depletion.   This study concluded that OC-TBI is a...

Read More

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the antibody response to a third mRNA COVID-19 vaccine of patients with chronic lymphocytic leukemia (CLL) who had failed to achieve an antibody response after the standard two-dose vaccination regimen.  This study concluded that approximately a quarter of patients responded to the third...

Read More